Get started
Author

Monique A.J. van der Vleuten

Observed names: M. van der Vleuten, Monique A. J. van der Vleuten, Monique A.J. Van der Vleuten, Monique Van Der Vleuten, Monique van der Vleuten
ORCID: 0009-0007-4733-7208
Observed ORCID: 0009-0007-4733-7208
OpenAlex ID: A5042814751
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2015 · Miranda M.C. van der Lee, Patrick G. Groothuis, et al. · Molecular Cancer Therapeutics · 205
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
2014 · Wim Dokter, Ruud Ubink, et al. · Molecular Cancer Therapeutics · 168
CYP7B expression and activity in fibroblast‐like synoviocytes from patients with rheumatoid arthritis: Regulation by proinflammatory cytokines
2005 · John Dulos, Monique A. J. van der Vleuten, et al. · Arthritis & Rheumatism · 58
PDF
Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice
2018 · Ruud Ubink, Eef H.C. Dirksen, et al. · Molecular Cancer Therapeutics · 48
PDF
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
2023 · Mary J van Helden, Seline A Zwarthoff, et al. · Journal for ImmunoTherapy of Cancer · 25
PDF
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al. · Molecular Cancer Therapeutics · 13
PDF
Glucose Kinetics in the Collagen-Induced Arthritis Model: An All-in-One Model to Assess Both Efficacy and Metabolic Side Effects of Glucocorticoids
2014 · Erik J. M. Toonen, Anke J. Laskewitz, et al. · PLoS ONE · 7
PDF
Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate
2021 · Patrick Groothuis, Danielle Jacobs, et al. · Cancer Research · 5
Abstract 926: BYON3521, a novel effective and safe c-Met targeting antibody-drug conjugate
2021 · Patrick Groothuis, Danielle Jacobs, et al. · Cancer Research · 4
Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia
2023 · Miranda van der Lee, Tanja van Achtenberg, et al. · Blood · 3
195P Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
2024 · E. Colas, C.P. Moiola, et al. · Annals of Oncology · 2
PDF
Abstract 2652: In vitro and in vivo antitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1
2014 · Willem H.A. Dokter, Miranda van der Lee, et al. · Cancer Research · 2
Abstract 2651: Impressive efficacy and safety profile of a novel generation duocarmycin-based HER2-targeting ADC
2014 · Willem Dokter, Ruud Ubink, et al. · Cancer Research · 2
Abstract 3129: BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines
2024 · Miranda M.C. van der Lee, Tanja van Achterberg, et al. · Cancer Research · 1
Abstract 4043: SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs)
2020 · Wim H. Dokter, Fred A. Dijcks, et al. · Cancer Research · 1
Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
2015 · Willem Dokter, Miranda van der Lee, et al. · Cancer Research · 1
A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer
2026 · Cristian Pablo Moiola, Carlos Lopez-Gil, et al. · Biomedicine & Pharmacotherapy
PDF
Abstract 3178: Antifolate ADCs, a novel linker-drug platform for targeted therapy with a clear differentiating mechanism of action
2026 · Ronald C. Elgersma, Renier C. Heijkants, et al. · Cancer Research
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2025 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
547 Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
2024 · Cristian Pablo Moiola, Carlos Lopez-Gil, et al. · International Journal of Gynecological Cancer
PDF
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Works count: 38
Citation count: 545
H-index: 7
I10-index: 6
Year
Topic
Type